KPTI

Karyopharm Therapeutics Inc

0.4244

Oct 21 • 3:59 PM ET +0.0658 (18.35%)

0.4301

Aftermarket • 7:58 PM ET +0.0057 (1.34%)

Healthcare Biotechnology USA Nano NASD

Peers: PBYI GERN CHRS VSTM SNDX RIGL KURA BYSI SLS CRIS

| Held by: VTI VXF IWM VTWO FESM IWN IWC QQQS VTWV OMFS

Scroll to Statements

Index	RUT
Market Cap	9.62M
Enterprise Value	200.70M
Income	-224.74M
Sales	146.62M
Book/sh	-14.56
Cash/sh	2.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	228
IPO	Nov 06, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	0.07
P/B	-
P/C	0.15
P/FCF	-
EV/EBITDA	-
EV/Sales	1.37
Quick Ratio	0.76
Current Ratio	0.79
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-13.08
EPS next Y	-2.27
EPS next Q	-0.95
EPS this Y	72.99%
EPS next Y	53.13%
EPS next 5Y	60.92%
EPS past 3/5Y	16.03% 15.19%
Sales past 3/5Y	-2.39% 6.21%
EPS Y/Y TTM	11.95%
Sales Y/Y TTM	6.81%
EPS Q/Q	46.41%
Sales Q/Q	-11.86%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-69.13% 3.85%

Insider Own	16.91%
Insider Trans	-0.25%
Inst Own	86.13%
Inst Trans	11.40%
ROA	-207.90%
ROE	-
ROIC	-
Gross Margin	95.89%
Oper. Margin	-56.17%
Profit Margin	-153.28%
SMA20	-44.71%
SMA50	-69.82%
SMA200	-93.25%
Trades

Shs Outstand	22.68M
Shs Float	18.85M
Short Float	32.13%
Short Ratio	3.37
Short Interest	6.06M
52W High	10.99 -96.14%
52W Low	0.31 36.90%
Volatility	18.04% 18.19%
ATR (14)	0.13
RSI (14)	23.70
Beta	1.10
Rel Volume	0.90
Avg Volume	1.80M
Volume	1,616,521

Perf Week	34.73%
Perf Month	-76.68%
Perf Quarter	-94.01%
Perf Half Y	-95.56%
Perf YTD	-94.23%
Perf Year	-93.40%
Perf 3Y	-97.33%
Perf 5Y	-99.47%
Perf 10Y	-99.67%
Recom	1.33
Target Price	8.80
Prev Close	0.36
Price	0.42
Change %	18.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-26	Downgrade	Robert W. Baird	Outperform → Neutral	$3
Jul-31-26	Downgrade	H.C. Wainwright	Buy → Neutral	$3
Mar-10-26	Initiated	Rodman & Renshaw	Buy	$28
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy	$15
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy	$27
Jan-19-23	Initiated	Piper Sandler	Overweight	$8
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral	$8
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$27 → $10
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$6
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$17 → $8
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-02-20	Initiated	Morgan Stanley	Overweight	$34
Mar-04-20	Initiated	Barclays	Overweight	$30
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight	$8 → $16
Jul-05-19	Reiterated	Robert W. Baird	Outperform	$15 → $25
Jul-05-19	Reiterated	H.C. Wainwright	Buy	$29 → $32

Show Previous Ratings

Oct-01-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -28.95% -7.45%
Sep-11-26 05:37AM	Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use (BioPharma Dive)
Sep-01-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -10.19%
Aug-31-26 07:30AM	Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis (PR Newswire) +10.16%
Aug-14-26 08:30AM	Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary (Moby)
07:09PM	Loading…
Aug-13-26 07:09PM	Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... (GuruFocus.com)
07:48AM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press)
07:30AM	Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission (PR Newswire)
Aug-10-26 07:30AM	Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 (PR Newswire) -7.55%
Aug-03-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-31-26 07:02AM	Karyopharms XPORT-EC-042 study fails to meet primary endpoint (Clinical Trials Arena) -72.61%
Jul-30-26 06:27PM	Why Is KPTI Stock Down 69% After-Hours Today? (Stocktwits)
04:06PM	Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway (PR Newswire)
04:05PM	Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer (PR Newswire)
Jul-01-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
04:15PM	Loading…
Jun-03-26 04:15PM	Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 (PR Newswire)
Jun-02-26 10:02AM	Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 (PR Newswire) -6.01%
08:59AM	Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology (PR Newswire)
Jun-01-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.91%
07:30AM	Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation (PR Newswire)
May-28-26 11:29AM	Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet (Quartz)
07:30AM	Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-14-26 07:04PM	Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -13.82%
05:19PM	Karyopharm Therapeutics Inc. Q1 2026 Earnings Call Summary (Moby)
07:40AM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment (PR Newswire)
May-12-26 07:30AM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire)
May-07-26 07:30AM	Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 (PR Newswire)
Apr-21-26 10:32AM	Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting (PR Newswire)
Mar-31-26 08:07PM	Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? (Quartz) +5.09%
07:01AM	Loading…
Mar-24-26 07:01AM	Karyopharm Announces $30 Million Private Placement with RA Capital (PR Newswire) -18.32%
07:00AM	Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction (PR Newswire)
05:47AM	Karyopharm myeloma drug yields mixed data in myelofibrosis trial (BioPharma Dive)
Mar-02-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-23-26 09:09PM	Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting (MarketBeat)
Feb-18-26 09:55AM	Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade (Zacks)
Feb-12-26 02:01PM	Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com) +21.30%
01:02PM	Karyopharm Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:33PM	Karyopharm Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
08:45AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:47AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Feb-05-26 07:30AM	Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 (PR Newswire)
Feb-02-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-12-26 07:00AM	Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 (PR Newswire) -5.59%
Jan-02-26 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-08-25 07:00AM	Karyopharm to Participate in Baird's Biotech Discovery Series (PR Newswire)
Dec-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.78%
07:00AM	Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-07-25 08:01PM	Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +5.43%
Nov-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.92%
07:06AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Oct-31-25 09:35AM	Earnings To Watch: Karyopharm Therapeutics Inc (KPTI) Reports Q3 2025 Result (GuruFocus.com)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 07:00AM	Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 (PR Newswire)
Oct-17-25 09:55AM	Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Oct-08-25 07:00AM	Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Oct-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.05%
Sep-24-25 03:48AM	Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? (Zacks) -8.02%
Sep-11-25 07:40AM	Karyopharm concludes enrolment in Phase III myelofibrosis treatment trial (Clinical Trials Arena) +6.92%
Sep-10-25 07:00AM	Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Sep-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-12-25 03:03AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +6.63%
Aug-11-25 07:00PM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:57PM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-08-25 09:33AM	Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-07-25 08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-05-25 07:00AM	Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 (PR Newswire)
Aug-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-30-25 07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
Jul-29-25 10:00AM	Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) -5.49%
Jul-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.73%
Jun-03-25 08:00AM	Karyopharm to Present at the Jefferies Global Healthcare Conference (PR Newswire)
Jun-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-25 09:55AM	Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-19-25 09:55AM	Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? (Zacks)
07:00AM	Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-14-25 09:31AM	Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting (PR Newswire)
May-13-25 03:08AM	Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com) -20.00%
May-12-25 05:25PM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification (PR Newswire)
May-08-25 04:05PM	Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 (PR Newswire)
May-05-25 05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks) -11.57%
May-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.88%
Apr-01-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.35% +14.69%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.81% -12.14%
Feb-24-25 08:40AM	Karyopharm Announces 1-for-15 Reverse Stock Split (PR Newswire)
Feb-20-25 02:03AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
01:39AM	Q4 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 11:45AM	Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress (PR Newswire)
04:59AM	Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-12-25 07:00AM	Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 (PR Newswire)
Feb-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Abate Kristin	Chief Accounting Officer	Oct 16 '26	Sale	0.34	4,788	1,647	18,616	Oct 19 04:03 PM
Abate Kristin	Chief Accounting Officer	Oct 01 '26	Sale	1.19	378	450	23,404	Oct 02 04:01 PM
Abate Kristin	Chief Accounting Officer	Sep 01 '26	Sale	2.02	19	38	23,782	Sep 02 04:57 PM
Poulton Stuart	EVP, Chief Development Officer	Jul 28 '26	Sale	7.10	189	1,342	94,632	Jul 30 04:42 PM
Poulton Stuart	EVP, Chief Development Officer	May 14 '26	Sale	9.50	403	3,828	94,821	May 15 04:08 PM
Rangwala Reshma	EVP & Chief Medical Officer	May 14 '26	Sale	9.50	408	3,876	56,829	May 15 04:07 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	May 14 '26	Sale	9.50	324	3,078	107,940	May 15 04:05 PM
Abate Kristin	Chief Accounting Officer	May 14 '26	Sale	9.50	53	504	23,801	May 15 04:04 PM
Paulson Richard A.	President and CEO	May 14 '26	Sale	9.50	2,203	20,928	269,747	May 15 04:03 PM
Mano Michael	EVP, CLO&Secretary	May 14 '26	Sale	9.50	266	2,527	94,398	May 15 04:02 PM
Rangwala Reshma	EVP & Chief Medical Officer	Apr 21 '26	Sale	8.94	449	4,014	56,290	Apr 22 04:03 PM
Mano Michael	EVP, CLO&Secretary	Mar 02 '26	Sale	9.41	3,526	33,178	93,964	Mar 03 04:28 PM
Rangwala Reshma	EVP & Chief Medical Officer	Mar 02 '26	Sale	9.41	5,066	47,669	56,739	Mar 03 04:25 PM
Paulson Richard A.	President and CEO	Mar 02 '26	Sale	9.41	12,361	116,311	267,030	Mar 03 04:21 PM
Poulton Stuart	EVP, Chief Development Officer	Feb 17 '26	Sale	8.63	378	3,262	99,429	Feb 19 04:02 PM
Macomber Lori	EVP, CFO & Treasurer	Feb 03 '26	Sale	6.30	1,626	10,244	85,105	Feb 04 04:11 PM
Abate Kristin	Chief Accounting Officer	Jan 28 '26	Sale	7.03	50	352	22,622	Jan 29 04:57 PM
Abate Kristin	Chief Accounting Officer	Jan 21 '26	Sale	5.96	265	1,579	22,580	Jan 22 04:09 PM

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

PresidentMr. Richard A. Paulson M.B.A.

Executive VP & Chief Development OfficerMr. Stuart Poulton

Ph.D.Dr. Reshma Rangwala M.D.

Ph.D.Dr. Sharon Shacham M.B.A.

EVPMs. Lori A. Macomber CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KPTI

Karyopharm Therapeutics Inc

Upgrade your Finviz experience